Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Genes</td><td class="align_center">CDS</td><td class="align_center">Amino acid</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">PIK3CA</td><td class="align_center">Exon21:c.A3140G</td><td class="align_center">p.H1047R</td></tr><tr><td class="align_left">BRAF</td><td class="align_center">Exon15:c.T1799A</td><td class="align_center">p.V600E</td></tr><tr><td class="align_left">CDKN2A</td><td class="align_center">Exon2:c.C172T</td><td class="align_center">p.R58X</td></tr><tr><td class="align_left">TP53</td><td class="align_center">Exon5:c.G438A</td><td class="align_center">p.W146X</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Case Reports in Oncological Medicine

tab1

Table 1

Table 1: Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation 